Seurat Therapeutics has published data from studies of its intranasal IGF-1 in rat models for the treatment of migraine in the journal Brain Research. The studies were conducted at the University of Chicago, which has licensed patents for the use of nasal IGF-1 to treat migraines to Seurat. According to the article, the formulation demonstrated the potential of … [Read more...] about Seurat reports data from preclinical studies of intranasal IGF-1
Medical
Koura announces clinical trial plans for Zephex 152a
Koura (formerly Mexichem Fluor) announced that the FDA has cleared the company's IND for Zephex HFA 152a MDI propellant, and the company plans to initiate clinical trials of the propellant this month. In December 2019, Chiesi announced that it intended to bring a Zephex 152a inhaler to market by the end of 2025. At DDL 2016, Koura presented data suggesting the … [Read more...] about Koura announces clinical trial plans for Zephex 152a
Pulmotect says that preclinical testing of its PUL-042 inhaled immune stimulant shows potential against coronavirus infections
Pulmotect has announced that preclinical testing in mouse models has demonstated that a single dose of its PUL-042 inhaled immunostimulant, which is made up of Toll-like receptor ligands, could protect against infection by SARS-associated coronavirus and by MERS-associated coronavirus. Post-infection, PUL-042 also reduced the amount of virus in the lungs for both of … [Read more...] about Pulmotect says that preclinical testing of its PUL-042 inhaled immune stimulant shows potential against coronavirus infections
Positive results for Phase 2b trial of nebulized ensifentrine as add-on to tiotropium
Verona Pharma said that a Phase 2b dose-ranging study of its RPL554 nebulized ensifentrine as an add on to tiotropium for the treatment of COPD met its primary endpoint at all doses tested. The company had announced initiation of the study in May 2019. The 4 week study, which enrolled 416 moderate-to-severe COPD patients, compared 0.375 mg, 0.75 mg, 1.5 mg, and … [Read more...] about Positive results for Phase 2b trial of nebulized ensifentrine as add-on to tiotropium
Phase 2 study of Oyster Point’s OC-01 nasal spray for dry eye disease meets primary endpoint
According to Oyster Point Pharma, the Phase 2 MYSTIC study of its OC-01 varenicline nasal spray for the treatment of dry eye disease met its primary endpoint, demonstrating significant improvement in tear production at Day 84 compared to control as measured by Schirmer's score. Both doses tested met that endpoint, with a 1.2 mg/ml dose achieving an 11.0 mm mean change … [Read more...] about Phase 2 study of Oyster Point’s OC-01 nasal spray for dry eye disease meets primary endpoint
AI Therapeutics provides update on inhaled rapamycin
AI Therapeutics (formerly LAM Therapeutics) said that it is seeking a partner to advance its LAM-001 inhaled rapamycin into Phase 3 trials for the treatment of lymphangioleiomyomatosis (LAM disease) and into Phase 2 for the treatment of pulmonary arterial hypertension (PAH). The company said that LAM-001 has been granted Orphan Drug designation for LAM in Europe and … [Read more...] about AI Therapeutics provides update on inhaled rapamycin
Positive topline results for Phase 2/3 trial of Biohaven’s intranasal vazegepant for migraine
Biohaven Pharmaceutical has announced that a Phase 2/3 trial of its intranasal vazegepant (BHV-3500) demonstrated that 10 and 20 mg doses of the intranasal migraine therapy were more effective than placebo for pain relief and that the drug was well tolerated with no indication of liver toxicity. Biohaven announced the initiation of the study in April 2019. The … [Read more...] about Positive topline results for Phase 2/3 trial of Biohaven’s intranasal vazegepant for migraine
Phase 2 trial of Theravance’s TD-8236 inhaled JAK inhibitor gets underway
Theravance Biopharma announced that the first patient has been dosed in a Phase 2 study of its TD-8236 inhaled dry powder pan-JAK inhibitor which the company is developing for the treatment of inflammatory lung diseases. In September 2019, the company announced positive results from a Phase 1 SAD/MAD study of TD-8236. The Phase 2 allergen challenge study will … [Read more...] about Phase 2 trial of Theravance’s TD-8236 inhaled JAK inhibitor gets underway
Otitopic announces results from Phase 1 trial of its inhaled aspirin
Otitopic has announced that a Phase 1 trial of its Asprihale dry powder aspirin found that the inhaled formulation demonstrated antithrombotic effects at 2 minutes post dose compared to 30 minutes post dose for a 162 mg chewable aspirin tablet. Both the inhaled and chewable aspirin maintained maximum antithrombotic effects at 24 hours post dose. In February 2019, … [Read more...] about Otitopic announces results from Phase 1 trial of its inhaled aspirin
TFF initiates Phase 1 trial of inhaled voriconazole
TFF Pharmaceuticals has announced the initiation of Phase 1 trial of its dry powder voriconazole, which the company is developing for the treatment of invasive pulmonary aspergillosis (IPA). The Phase I SAD/MAD study will be conducted in Canada and will enroll a total of 64 healthy subjects, 32 in each part. The company recently raised $22 million in an initial … [Read more...] about TFF initiates Phase 1 trial of inhaled voriconazole